Incyte Corporation

INCY

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 1, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Pembrolizumab	Phase 3	Head and Neck Cancer	-
INCA034176	Phase 3	Chronic Graft-versus-host-disease	-
Sunitinib	Phase 3	Renal Cell Carcinoma (RCC)	-
Povorcitinib	Phase 3	NonSegmental Vitiligo	-
pembrolizumab + epacadostat	Phase 3	Melanoma	-
Pemetrexed	Phase 3	Metastatic Squamous Non-Small Cell Lung Cancer	-
Lenalidomide	Phase 3	Large B-Cell Lymphoma	-
Vehicle Cream	Phase 3	Prurigo Nodularis	-
Vehicle	Phase 3	Non-segmental Vitiligo	-
ruxolitinib tablets	Phase 3	Polycythemia Vera	-
Cyclophosphamide	Phase 3	Diffuse Large B-cell Lymphoma	-
Extracorporeal photopheresis (ECP)	Phase 3	Graft-versus-host Disease (GVHD)	-
rituximab	Phase 3	Follicular Lymphoma	-
Rituximab (RTX)	Phase 3	Diffuse Large B-cell Lymphoma	-
Ruxolitinib	Phase 2	MPN (Myeloproliferative Neoplasms)	-
Ruxolitinib phosphate cream	Phase 2	Psoriasis	-
INCB054707	Phase 2	Hidradenitis Suppurativa	-
Parsaclisib	Phase 2	B-Cell Malignancies	-
Ponatinib	Phase 2	Philadelphia Positive	-
Ruxolitinib 0.15% Cream QD	Phase 2	Atopic Dermatitis	-
INCB009471	Phase 2	HIV Infections	-
INCB018424	Phase 2	Rheumatoid Arthritis	-
INCB028050	Phase 2	Rheumatoid Arthritis	-
Prednisone or methylprednisolone	Phase 2	Graft-versus-host Disease (GVHD)	-
Epacadostat	Phase 2	Lung Cancer	-
Ruxolitinib Phosphate	Phase 2	Psoriasis	-
Ruxolitinib Cream	Phase 2	Nonsegmental Vitiligo With Genital Involvement	-
Platinum-based chemotherapy	Phase 2	Lung Cancer	-
Capecitabine	Phase 2	Pancreatic Cancer	-
parsaclisib + itacitinib	Phase 2	B-Cell Malignancies	-
Immune effector cell therapy	Phase 2	Cytokine Release Syndrome	-
Retifanlimab	Phase 2	Metastatic Merkel Cell Carcinoma	-
Itacitinib	Phase 2	MPN (Myeloproliferative Neoplasms)	-
INCB001158	Phase 2	Biliary Tract Cancer (BTC)	-
Placebo	Phase 2	Hidradenitis Suppurativa	-
INCB177054	Phase 2	Solid Tumors	-
ICS-LABA	Phase 2	Moderate to Severe Asthma	-
Pemigatinib	Phase 2	Non-Small Cell Lung Cancer (NSCLC)	-
Ruxolitinib 25 mg	Phase 2	Multiple Myeloma	-
Nivolumab	Phase 2	B-cell Malignancies	-
Tafasitamab	Phase 2	Diffuse Large B Cell Lymphoma	-
Asparaginase Erwinia Chrysanthemi	Phase 2	Leukemia	-
INCB013739	Phase 2	Type 2 Diabetes	-
INCB000928	Phase 2	Anemia	-

Catalyst Timeline

21 upcoming, 0 past

Phase 2Next

Asparaginase Erwinia Chrysanthemi Phase 2 Results Expected

Feb 1, 2026Asparaginase Erwinia Chrysanthemi

Primary completion for Asparaginase Erwinia Chrysanthemi trial (NCT02723994) in Leukemia

Source

Phase 2

Ruxolitinib Phase 2 Results Expected

Feb 1, 2026Ruxolitinib

Primary completion for Ruxolitinib trial (NCT02723994) in Leukemia

Source

⭐Phase 3

Povorcitinib Phase 3 Results Expected

Mar 17, 2026Povorcitinib

Primary completion for Povorcitinib trial (NCT06113445) in NonSegmental Vitiligo

Source

⭐Phase 3

Placebo Phase 3 Results Expected

Mar 17, 2026Placebo

Primary completion for Placebo trial (NCT06113471) in NonSegmental Vitiligo

Source

⭐Phase 3

Tafasitamab Phase 3 Results Expected

Apr 1, 2026Tafasitamab

Primary completion for Tafasitamab trial (NCT05429268) in Large B-Cell Lymphoma

Source

⭐Phase 3

Lenalidomide Phase 3 Results Expected

Apr 1, 2026Lenalidomide

Primary completion for Lenalidomide trial (NCT05429268) in Large B-Cell Lymphoma

Source

Phase 2

povorcitinib Phase 2 Results Expected

Jun 15, 2026Povorcitinib

Primary completion for povorcitinib trial (NCT05851443) in Moderate to Severe Asthma

Source

Phase 2

ICS-LABA Phase 2 Results Expected

Jun 15, 2026ICS-LABA

Primary completion for ICS-LABA trial (NCT05851443) in Moderate to Severe Asthma

Source

Phase 2

itacitinib Phase 2 Results Expected

Jun 22, 2026Itacitinib

Primary completion for itacitinib trial (NCT04640025) in Myelofibrosis

Source

Phase 2

INCA034176 Phase 2 Results Expected

Jul 3, 2026INCA034176

Primary completion for INCA034176 trial (NCT06843408) in Chronic Graft-versus-host-disease

Source

⭐Phase 3

Vehicle Cream Phase 3 Results Expected

Jul 13, 2026Vehicle Cream

Primary completion for Vehicle Cream trial (NCT06548360) in NonSegmental Vitiligo

Source

⭐Phase 3

Ruxolitinib Phase 3 Results Expected

Jul 13, 2026Ruxolitinib

Primary completion for Ruxolitinib trial (NCT06832618) in Atopic Dermatitis

Source

⭐Phase 3

Ruxolitinib Cream Phase 3 Results Expected

Aug 10, 2026Ruxolitinib Cream

Primary completion for Ruxolitinib Cream trial (NCT06548360) in NonSegmental Vitiligo

Source

⭐Phase 3

Tafasitamab Phase 3 Results Expected

Sep 1, 2026Tafasitamab

Primary completion for Tafasitamab trial (NCT04824092) in Diffuse Large B-cell Lymphoma

Source

⭐Phase 3

Lenalidomide Phase 3 Results Expected

Sep 1, 2026Lenalidomide

Primary completion for Lenalidomide trial (NCT04824092) in Diffuse Large B-cell Lymphoma

Source

⭐Phase 3

Cyclophosphamide Phase 3 Results Expected

Sep 1, 2026Cyclophosphamide

Primary completion for Cyclophosphamide trial (NCT04824092) in Diffuse Large B-cell Lymphoma

Source

⭐Phase 3

Rituximab Phase 3 Results Expected

Sep 1, 2026rituximab

Primary completion for Rituximab trial (NCT04824092) in Diffuse Large B-cell Lymphoma

Source

⭐Phase 3

Ruxolitinib Cream Phase 3 Results Expected

Oct 9, 2026Ruxolitinib Cream

Primary completion for Ruxolitinib Cream trial (NCT06959225) in Hidradenitis Suppurativa

Source

⭐Phase 3

Vehicle Cream Phase 3 Results Expected

Oct 9, 2026Vehicle Cream

Primary completion for Vehicle Cream trial (NCT06959225) in Hidradenitis Suppurativa

Source

⭐Phase 3

Placebo Phase 3 Results Expected

Oct 19, 2026Placebo

Primary completion for Placebo trial (NCT06516965) in Prurigo Nodularis

Source

⭐Phase 3

Povorcitinib Phase 3 Results Expected

Oct 19, 2026Povorcitinib

Primary completion for Povorcitinib trial (NCT06516965) in Prurigo Nodularis

Source

Regulatory Approvals

INCY News

Incyte Corporation

INCY

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 1, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Pembrolizumab	Phase 3	Head and Neck Cancer	-
INCA034176	Phase 3	Chronic Graft-versus-host-disease	-
Sunitinib	Phase 3	Renal Cell Carcinoma (RCC)	-
Povorcitinib	Phase 3	NonSegmental Vitiligo	-
pembrolizumab + epacadostat	Phase 3	Melanoma	-
Pemetrexed	Phase 3	Metastatic Squamous Non-Small Cell Lung Cancer	-
Lenalidomide	Phase 3	Large B-Cell Lymphoma	-
Vehicle Cream	Phase 3	Prurigo Nodularis	-
Vehicle	Phase 3	Non-segmental Vitiligo	-
ruxolitinib tablets	Phase 3	Polycythemia Vera	-
Cyclophosphamide	Phase 3	Diffuse Large B-cell Lymphoma	-
Extracorporeal photopheresis (ECP)	Phase 3	Graft-versus-host Disease (GVHD)	-
rituximab	Phase 3	Follicular Lymphoma	-
Rituximab (RTX)	Phase 3	Diffuse Large B-cell Lymphoma	-
Ruxolitinib	Phase 2	MPN (Myeloproliferative Neoplasms)	-
Ruxolitinib phosphate cream	Phase 2	Psoriasis	-
INCB054707	Phase 2	Hidradenitis Suppurativa	-
Parsaclisib	Phase 2	B-Cell Malignancies	-
Ponatinib	Phase 2	Philadelphia Positive	-
Ruxolitinib 0.15% Cream QD	Phase 2	Atopic Dermatitis	-
INCB009471	Phase 2	HIV Infections	-
INCB018424	Phase 2	Rheumatoid Arthritis	-
INCB028050	Phase 2	Rheumatoid Arthritis	-
Prednisone or methylprednisolone	Phase 2	Graft-versus-host Disease (GVHD)	-
Epacadostat	Phase 2	Lung Cancer	-
Ruxolitinib Phosphate	Phase 2	Psoriasis	-
Ruxolitinib Cream	Phase 2	Nonsegmental Vitiligo With Genital Involvement	-
Platinum-based chemotherapy	Phase 2	Lung Cancer	-
Capecitabine	Phase 2	Pancreatic Cancer	-
parsaclisib + itacitinib	Phase 2	B-Cell Malignancies	-
Immune effector cell therapy	Phase 2	Cytokine Release Syndrome	-
Retifanlimab	Phase 2	Metastatic Merkel Cell Carcinoma	-
Itacitinib	Phase 2	MPN (Myeloproliferative Neoplasms)	-
INCB001158	Phase 2	Biliary Tract Cancer (BTC)	-
Placebo	Phase 2	Hidradenitis Suppurativa	-
INCB177054	Phase 2	Solid Tumors	-
ICS-LABA	Phase 2	Moderate to Severe Asthma	-
Pemigatinib	Phase 2	Non-Small Cell Lung Cancer (NSCLC)	-
Ruxolitinib 25 mg	Phase 2	Multiple Myeloma	-
Nivolumab	Phase 2	B-cell Malignancies	-
Tafasitamab	Phase 2	Diffuse Large B Cell Lymphoma	-
Asparaginase Erwinia Chrysanthemi	Phase 2	Leukemia	-
INCB013739	Phase 2	Type 2 Diabetes	-
INCB000928	Phase 2	Anemia	-

Catalyst Timeline

21 upcoming, 0 past

Phase 2Next

Asparaginase Erwinia Chrysanthemi Phase 2 Results Expected

Feb 1, 2026Asparaginase Erwinia Chrysanthemi

Primary completion for Asparaginase Erwinia Chrysanthemi trial (NCT02723994) in Leukemia

Source

Phase 2

Ruxolitinib Phase 2 Results Expected

Feb 1, 2026Ruxolitinib

Primary completion for Ruxolitinib trial (NCT02723994) in Leukemia

Source

⭐Phase 3

Povorcitinib Phase 3 Results Expected

Mar 17, 2026Povorcitinib

Primary completion for Povorcitinib trial (NCT06113445) in NonSegmental Vitiligo

Source

⭐Phase 3

Placebo Phase 3 Results Expected

Mar 17, 2026Placebo

Primary completion for Placebo trial (NCT06113471) in NonSegmental Vitiligo

Source

⭐Phase 3

Tafasitamab Phase 3 Results Expected

Apr 1, 2026Tafasitamab

Primary completion for Tafasitamab trial (NCT05429268) in Large B-Cell Lymphoma

Source

⭐Phase 3

Lenalidomide Phase 3 Results Expected

Apr 1, 2026Lenalidomide

Primary completion for Lenalidomide trial (NCT05429268) in Large B-Cell Lymphoma

Source

Phase 2

povorcitinib Phase 2 Results Expected

Jun 15, 2026Povorcitinib

Primary completion for povorcitinib trial (NCT05851443) in Moderate to Severe Asthma

Source

Phase 2

ICS-LABA Phase 2 Results Expected

Jun 15, 2026ICS-LABA

Primary completion for ICS-LABA trial (NCT05851443) in Moderate to Severe Asthma

Source

Phase 2

itacitinib Phase 2 Results Expected

Jun 22, 2026Itacitinib

Primary completion for itacitinib trial (NCT04640025) in Myelofibrosis

Source

Phase 2

INCA034176 Phase 2 Results Expected

Jul 3, 2026INCA034176

Primary completion for INCA034176 trial (NCT06843408) in Chronic Graft-versus-host-disease

Source

⭐Phase 3

Vehicle Cream Phase 3 Results Expected

Jul 13, 2026Vehicle Cream

Primary completion for Vehicle Cream trial (NCT06548360) in NonSegmental Vitiligo

Source

⭐Phase 3

Ruxolitinib Phase 3 Results Expected

Jul 13, 2026Ruxolitinib

Primary completion for Ruxolitinib trial (NCT06832618) in Atopic Dermatitis

Source

⭐Phase 3

Ruxolitinib Cream Phase 3 Results Expected

Aug 10, 2026Ruxolitinib Cream

Primary completion for Ruxolitinib Cream trial (NCT06548360) in NonSegmental Vitiligo

Source

⭐Phase 3

Tafasitamab Phase 3 Results Expected

Sep 1, 2026Tafasitamab

Primary completion for Tafasitamab trial (NCT04824092) in Diffuse Large B-cell Lymphoma

Source

⭐Phase 3

Lenalidomide Phase 3 Results Expected

Sep 1, 2026Lenalidomide

Primary completion for Lenalidomide trial (NCT04824092) in Diffuse Large B-cell Lymphoma

Source

⭐Phase 3

Cyclophosphamide Phase 3 Results Expected

Sep 1, 2026Cyclophosphamide

Primary completion for Cyclophosphamide trial (NCT04824092) in Diffuse Large B-cell Lymphoma

Source

⭐Phase 3

Rituximab Phase 3 Results Expected

Sep 1, 2026rituximab

Primary completion for Rituximab trial (NCT04824092) in Diffuse Large B-cell Lymphoma

Source

⭐Phase 3

Ruxolitinib Cream Phase 3 Results Expected

Oct 9, 2026Ruxolitinib Cream

Primary completion for Ruxolitinib Cream trial (NCT06959225) in Hidradenitis Suppurativa

Source

⭐Phase 3

Vehicle Cream Phase 3 Results Expected

Oct 9, 2026Vehicle Cream

Primary completion for Vehicle Cream trial (NCT06959225) in Hidradenitis Suppurativa

Source

⭐Phase 3

Placebo Phase 3 Results Expected

Oct 19, 2026Placebo

Primary completion for Placebo trial (NCT06516965) in Prurigo Nodularis

Source

⭐Phase 3

Povorcitinib Phase 3 Results Expected

Oct 19, 2026Povorcitinib

Primary completion for Povorcitinib trial (NCT06516965) in Prurigo Nodularis

Source

Regulatory Approvals

INCY News